Depression — Prevalence and Effect of Detecting Common Mental Disorders in Long-term Sickness Absence
Citation(s)
Søgaard HJ, Bech P Compensating for non-response in a study estimating the incidence of mental disorders in long-term sickness absence by a two-phased design. Scand J Public Health. 2010 Aug;38(6):625-32. doi: 10.1177/1403494810373673. Epub 2010 Jun 7.
Søgaard HJ, Bech P Predictive validity of common mental disorders screening questionnaire as a screening instrument in long term sickness absence. Scand J Public Health. 2010 Jun;38(4):375-85. doi: 10.1177/1403494809350520. Epub 2009 Oct 22.
Søgaard HJ, Bech P Psychiatric disorders in long-term sickness absence -- a population-based cross-sectional study. Scand J Public Health. 2009 Sep;37(7):682-9. doi: 10.1177/1403494809344357. Epub 2009 Aug 21.
Søgaard HJ, Bech P Psychometric analysis of common mental disorders -- Screening Questionnaire (CMD-SQ) in long-term sickness absence. Scand J Public Health. 2009 Nov;37(8):855-63. doi: 10.1177/1403494809344653. Epub 2009 Aug 28.
Søgaard HJ, Bech P The effect of detecting undetected common mental disorders on psychological distress and quality of life in long-term sickness absence: a randomised controlled trial. Scand J Public Health. 2010 Dec;38(8):845-56. doi: 10.1177/140349481
Søgaard HJ, Bech P The effect on length of sickness absence by recognition of undetected psychiatric disorder in long-term sickness absence. A randomized controlled trial. Scand J Public Health. 2009 Nov;37(8):864-71. doi: 10.1177/1403494809347551. Epub
Søgaard HJ Choosing screening instrument and cut-point on screening instruments. A comparison of methods. Scand J Public Health. 2009 Nov;37(8):872-80. doi: 10.1177/1403494809344442. Epub 2009 Aug 28.
Prevalence and Effect of Detecting Common Mental Disorders in Long-term Sickness Absence
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
